for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,404.00GBp

Change

15.80(+1.14%)

Volume

5,645,711

Today's Range

1,377.40

 - 

1,408.00

52 Week Range

1,190.80

 - 

1,528.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,388.20
Open
1,390.80
Volume
5,645,711
3M AVG Volume
122.53
Today's High
1,408.00
Today's Low
1,377.40
52 Week High
1,528.80
52 Week Low
1,190.80
Shares Out (MIL)
5,031.73
Market Cap (MIL)
69,850.49
Forward P/E
13.70
Dividend (Yield %)
5.76

Next Event

GlaxoSmithKline PLC at Sanford C Bernstein Strategic Decisions Conference (Virtual)

Latest Developments

More

SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial

Australia's Health Department Says It Has Approved Glaxosmithkline's COVID-19 Treatment, Sotrovimab (Xevudy)

iTeos Therapeutics's Unit Got Upfront Payment Of $625 Mln From Glaxosmithkline Intellectual Property Limited

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Global Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.55 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

30.8K

2019

33.8K

2020

34.1K

2021(E)

33.4K
EPS (GBp)

2018

119.400

2019

123.900

2020

115.900

2021(E)

101.220
Price To Earnings (TTM)
15.96
Price To Sales (TTM)
2.12
Price To Book (MRQ)
4.54
Price To Cash Flow (TTM)
11.39
Total Debt To Equity (MRQ)
165.72
LT Debt To Equity (MRQ)
132.94
Return on Investment (TTM)
9.78
Return on Equity (TTM)
6.27

Latest News

Latest News

BRIEF-GSK Announces £50m Investment In Renewable Energy And Carbon Reduction

* PRESS RELEASE: GSK ANNOUNCES MAJOR RENEWABLE ENERGY INVESTMENT AND LOW CARBON INHALER PROGRAMME ALONGSIDE LIFE SCIENCES SECTOR RACE TO ZERO ‘BREAKTHROUGH’ AT NYC CLIMATE WEEK

S. Korean COVID-19 vaccine in late-stage test against AstraZeneca shot

South Korea's SK Bioscience and Britain's GSK said on Tuesday the drugmakers had begun a late-stage trial of their COVID-19 vaccine candidate against AstraZeneca's approved shot, the second study of its kind globally.

BRIEF-SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial

* GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL

BRIEF-Australia's Health Department Says It Has Approved Glaxosmithkline's COVID-19 Treatment, Sotrovimab (Xevudy)

* AUSTRALIA'S HEALTH DEPARTMENT SAYS IT HAS APPROVED GLAXOSMITHKLINE'S COVID-19 TREATMENT, SOTROVIMAB (XEVUDY) Further company coverage:

GSK, CureVac's next-gen COVID-19 vaccine shows promise in monkey trial

GlaxoSmithKline and CureVac said a study https://www.curevac.com/wp-content/uploads/2021/08/Optimization-of-Non-Coding-Regions-Improves-Protective-Efficacy-of-an-mRNA-SARS-CoV-2-Vaccine-in-NHP.pdf on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine candidate...

BRIEF-Gsk - Files For Licensure Of Mmr Vaccine In U.S.

* GSK - SUBMITTED A BLA TO U.S. FDA FOR PRIORIX, SEEKING APPROVAL FOR USE IN ACTIVE IMMUNIZATION AGAINST INFECTION BY MEASLES, MUMPS AND RUBELLA (MMR) Source text for Eikon: Further company coverage:

BRIEF-Gsk Announces FDA Approval For Nucala For Use In Adults With Chronic Rhinosinusitis With Nasal Polyps

* GSK ANNOUNCES FDA APPROVAL FOR NUCALA (MEPOLIZUMAB) FOR USE IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Further company coverage:

Sanofi raises profit forecast after second quarter beat

Sanofi raised its 2021 profit forecast on Thursday after its vaccines and star eczema treatment Dupixent helped it beat second-quarter results expectations.

Covid boost offers GSK’s Walmsley Elliott relief

(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)

BRIEF-GSK Sees 2021 Adj EPS To Decline By Mid-To-High Single-Digit Percentage

* GSK SAYS CONTINUES TO EXPECT DIVIDEND OF 80P/SHARE FOR 2021

EU signs deal with GSK for supply of potential COVID drug

The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday.

BRIEF-GSK Sees 2021 Adj EPS To Decline By Mid-To-High Single-Digit Percentage

* Q2 ADJUSTED EARNINGS PER SHARE ROSE 46 PERCENT TO 28.1 PENCE

BRIEF-GSK And Vir Biotechnology Announce Joint Procurement Deal With European Commission For Sotrovimab

* GSK AND VIR BIOTECHNOLOGY ANNOUNCE JOINT PROCUREMENT AGREEMENT WITH EUROPEAN COMMISSION FOR COVID-19 TREATMENT, SOTROVIMAB

EU signs deal with GSK for supply of COVID potential drug

The European Union has signed a contract with GlaxoSmithKline for the supply of up to 220,000 treatments of its investigational monoclonal antibody therapy sotrovimab against COVID-19, it said on Wednesday.

BRIEF-GSK Appoints Brian Mcnamara As CEO Designate Of New Consumer Healthcare Co

* GLAXOSMITHKLINE PLC - CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.

BRIEF-GSK Says ViiV Healthcare Study Shows New Long-Acting HIV Regimen Cabenuva Can Be Used In US Healthcare Practices

* GSK-VIIV HEALTHCARE STUDY SHOWS NEW LONG-ACTING HIV REGIMEN CABENUVA CAN BE USED IN BROAD RANGE OF US HEALTHCARE PRACTICES, EVEN DURING COVID-19 Source text for Eikon: Further company coverage:

GSK anaemia drug shows promise as treatment in kidney disease patients

GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.

BRIEF-GlaxoSmithKline Announces Daprodustat Phase 3 Headline Results

* GLAXOSMITHKLINE PLC - GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS

Drugmaker GSK plans $550 million expansion of England R&D facility

Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up